Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
Year: 2022
Type: article
Abstract: Elevated androgen receptor (AR) expression is a hallmark of castration-resistant prostate cancer (CRPC) and contributes to the restoration of AR signaling under the conditions of androgen deprivation. However, whether overexpressed AR alone with the stimulation of castrate levels of androgens can be sufficient to induce the reprogramming of AR signaling for the adaptation of prostate cancer (PCa) cells remains unclear. In this study, we used a PCa model with inducible overexpression of AR to examine the acute effects of AR overexpression on its cistrome and transcriptome. Our results show that overexpression of AR alone in conjunction with lower androgen levels can rapidly redistribute AR chromatin binding and activates a distinct transcription program that is enriched for DNA damage repair pathways. Moreover, using a recently developed bioinformatic tool, we predicted the involvement of EZH2 in this AR reprogramming and subsequently identified a subset of AR/EZH2 co-targeting genes, which are overexpressed in CRPC and associated with worse patient outcomes. Mechanistically, we found that AR-EZH2 interaction is impaired by the pre-castration level of androgens but can be recovered by the post-castration level of androgens. Overall, our study provides new molecular insights into AR signaling reprogramming with the engagement of specific epigenetic factors.
Source: Frontiers in Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,950
Awards: FUNCTIONAL CHARACTERIZATION OF FORKHEAD-DOMAIN MISSENSE MUTATIONS OF FOXA1 IN DRIVING PROSTATE CANCER PROGRESSION, G1794103180, G3631430387, G3865632432, INHIBITING LYSINE-SPECIFIC DEMETHYLASE 1 ACTIVITY AS A POTENTIAL THERAPEUTIC TREATMENT FOR CASTRATION-RESISTANT PROSTATE CANCER, G4119534169, G4191669678, G4844777381, TARGETING FOXA1 METHYLATION IN CASTRATION-RESISTANT PROSTATE CANCER., G5850682332, G7930908297, G9000172661, G9000298429, G9000300237, G9000328023
OpenAlex ID: W4308416697
